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of treated patients. This benefit was impossible to quantify due to the fact
that neurological tools measures quality of changes in different systems
but not the quantity. During the one year follow-up period over 40% of
treated patients developed almost all symptoms that were present before
the procedure. It is interesting that initial benefit was associated with the
improvement in the biochemical parameters from the blood sample
analysis. This brain decongestions after “Liberation” procedure is prob-
ably the reason for relatively fast improvement in clinical signs that we see
in some group of treated patients.
Conclusions: The results obtained in this study suggest that CCSVI is
related to Brain Congestive Syndrome rather than MS indicating that
“Liberation” procedure may improve clinical signs in patients with MS
because of brain decongestion.
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Background: Chronic Venous Insufficiency (CVI) is a condition pres-
ent in almost 27% of adults in which an insufficient amount of blood is
pumped back to the heart due to damaged or poorly apposed one-way valves in
the leg veins. Valve repair consists of surgical correction of the malfunctioning
valves to improve their function. This generally requires a lengthy surgery and a
minimum of 4 days in the hospital. Vein transplants have proven to be effective,
however they require finding an intact donor valve, invasive surgery, and
hospitalization. A prosthetic vein valve may not require an invasive surgery,
human donor, or lengthy hospital stay.We describe the design, verification, and
preclinical validation tests of a novel prosthetic vein valve.
Methods: A new valve design is created which is naturally open, and is
impregnated with an anticoagulant compound. Verification tests include
competency, flow resistance, mechanical fatigue, and in vitro thromboge-
nicity tests. CFD analysis is used to quantify the amount of shear rates within
the valve that may induce platelet thrombogenicity. A sheep study has been
initiated to evaluate in vivo performance.
Results: The valve allows for physiologic flow rates of 400-600
mL/min as it poses little resistance to flow. The valve can tolerate
forward flow rates as high as 2800 mL/min. The valve is competent
under physiologic backpressures of 35 to 50 mmHg while maintaining an
acceptable level of reflux less than 40 mL/min. The valve withstands
500,000 cycles of fatigue testing without damage or loss of competency.
The new valve has computed wall shear rates below the threshold value of
4000 s1, which has been found to initiate thrombus formation by
platelet activation and aggregation in cardiovascular implants. This con-
trasts with other artificial values that have computed wall shear rates
exceeding 10,000 s1.
The valve has no measurable thrombogenicity to coagulation or
platelet adhesion with in vitro blood circulation testing in comparison
with alternative biomaterials and designs that occlude under identical
conditions. The valve with a stent can be delivered by catheter with no
migration under back and forward pressures of 100 mmHg. The valida-
tion of the device was done through an animal study in sheep external
jugular veins. In a sheep study, patency was found at 6 weeks, surpassing
many autograft valves.
Conclusions: A new prosthetic valve design shows promise for defin-
itive treatment of venous valvular disorders.
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Background: HP802-247 is a cell based therapy under development
for treatment of nonhealing venous leg ulcers. The product consists of
growth-arrested neonatal fibroblasts and keratinocytes, sprayed onto the
wound surface in a self-assembling fibrin matrix. A Phase 2 efficacy trial
involving 35 sites collected data on variables thought to influence response
to treatment.
Methods: 362 subjects were screened to enroll 228 into 5 intervention
groups (low dose biweekly (N46), low dose weekly (N43), high dose
biweekly (N44) high dose weekly (N45), or vehicle control (N50).
Biweekly dosing alternated with application of sprayed matrix control to main-
tain blinding. Treatment plus 4-layer compression bandage was administered
weekly for 12weeks or until healed.Outcomemeasures includeddays towound
closure and proportion of wounds healed after 12 weeks of treatment.
Results: Cell treatment (all groups pooled) was superior to vehicle.
Baseline wound area was significantly associated with days to wound
closure (P  .006) but did not affect the proportion of wounds healed at
12 weeks in a multiple logistic regression model (P  .12). Variables
influencing proportion healed in the model are listed below:
Table. Variables influencing proportion healed
Variable Range of values P value
Intervention Cells vs vehicle .004
Wound duration 6 to 104 weeks .001
Wound location Lower calf vs other sites .008
As an independent variable outside the model, baseline bacterial counts
(10,000 cfu/gm) of Escherichia, Enterobacter, Enterococcus, Morganella and
Pseudomonas species, or any-hemolytic Streptococcus, reduced the probability of
closure under either treatment (P.05, Chi square). The effect on relative risk
of failure (wound open)wasmore pronounced in the control group (RR 5.4)
than the cell treated group (RR 1.4). No subject who developed a clinically
evident wound infection closed their wound within 12 weeks. Variables found
to have no influence under the conditions of this study included debridement,
hemoglobin A1C, hemoglobin, serum creatinine, prealbumin, albumin, periph-
eral neuropathy, and body weight.
Conclusions: In this study, the variables influencing healing were
initial wound size, wound duration, wound location, and the addition of
cellular therapy to standard compression. The presence of certain bacteria in
the wound at screening inhibited healing, while an episode of infection
prevented healing within the 12 week study time frame. This information
may be used to predict healing potential of an ulcer at baseline, and in the
design of future intervention trials.
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Background: Pacific Vascular Symposium VI and American Venous
Forum (AVF) issued a call to reduce venous ulcers by 50% in ten years. A series
of recommendations were formulated. To measure the success of the venous
ulcer initiative, the ulcer prevalence has to be evaluated. TheOlmstedCounty in
Minnesota offers in this regard an exceptional opportunity: practically whole
population is included in the Rochester Epidemiological Project.
Methods: Preliminary data for the ulcer prevalence study was obtained
using 11 ICD-9 codes related to venous ulcer diagnosis and treatment
(454.0-2, 459.11-13, 459.31, 459.33, 459.81 and 707.9-10). The number
of venous ulcer cases per year was established from year 1991 to 2010. Each
patient was notified only once.
Further study will focus on patients from two last years. The review of
the medical charts will be performed to confirm the venous origin of ulcers.
The calculated prevalence will be extrapolated to the whole American
population taking into consideration demographic structure of the Olmsted
County and the entire country.
The study will be repeated after ten years period to measure the impact
of the Ulcer Initiative actions.
Results: Between 1991 and 2009/2010 the estimated prevalence of
venous ulcer per year varied from 0.26% to 1.48% (see Fig). In the same time
the population of the county increased considerably (106,966 in 1990 and
144,248 in 2010). The median age rose from 29 to 34 years for men and
from 31 to 36 for women.
Conclusions: In this preliminary data the estimated prevalence of
venous ulcers in Olmsted County had some fluctuations between 1991 and
2009/2010 with concomitant increase in the median age of the population.
Further study with the review of medical charts will establish the exact
current incidence and prevalence and will constitute the basis for global
estimation of the ulcer prevalence in the USA.
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